Kathleen Laporte - Sep 25, 2024 Form 4 Insider Report for CERO THERAPEUTICS HOLDINGS, INC. (CERO)

Role
Director
Signature
/s/ Kathleen LaPorte
Stock symbol
CERO
Transactions as of
Sep 25, 2024
Transactions value $
-$50,000
Form type
4
Date filed
10/2/2024, 09:53 PM
Previous filing
Sep 6, 2024
Next filing
Dec 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERO Common Stock Options Exercise +966K 966K Sep 25, 2024 By the Kathleen LaPorte Revocable Trust F1, F2
holding CERO Common Stock 5.83K Sep 25, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERO Series A Convertible Preferred Stock Options Exercise -$50K -50 -100% $1,000.00 0 Sep 25, 2024 Common Stock 966K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date.
F2 The reporting person is the trustee of the Kathleen LaPorte Revocable Trust (the "Trust") and has sole voting and disposition power with respect to the shares owned by the Trust.